BioNTech SE (BNTX) Cash & Equivalents (2018 - 2025)

BioNTech SE has disclosed Cash & Equivalents across 8 years of filings, most recently posting $8.9 billion for Q4 2025.

• Cash & Equivalents for Q4 2025 came in at $8.9 billion, down 14.35% year-over-year; the trailing twelve-month figure through Dec 2025 was $8.9 billion (down 14.35% YoY), and the FY2025 annual result was $8.7 billion, down 16.87% from the prior year.
• Cash & Equivalents came in at $8.9 billion for Q4 2025 at BioNTech SE, down from $12.0 billion in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $1459786.9 billion in Q1 2021 to a low of $1.4 billion in Q3 2021.
• The 5-year median for Cash & Equivalents is $11.8 billion (2025), against an average of $72998.7 billion.
• Across the five-year window, Cash & Equivalents tumbled 100.0% in 2022 and surged 683.92% in 2023, its largest moves.
• BioNTech SE's Cash & Equivalents stood at $1.9 billion in 2021, then soared by 631.05% to $14.2 billion in 2022, then retreated by 11.35% to $12.5 billion in 2023, then fell by 16.88% to $10.4 billion in 2024, then slipped by 14.35% to $8.9 billion in 2025.
• The last three Cash & Equivalents figures came in at $8.9 billion (Q4 2025), $12.0 billion (Q3 2025), and $11.5 billion (Q2 2025), per Business Quant data.